In esophageal adenocarcinoma (EAC), GLI-inhibitor (Gli-i) upregulated E-cadherin expression while downregulating N-cadherin and β-catenin expression by inhibiting GLI1 and GLI2 transcriptional activity. The gene discussed is GLI1; the disease is esophageal adenocarcinoma.